Capital Advantage buys $786,807 stake in Pfizer (PFE)

Pfizer (PFE) : Capital Advantage scooped up 6,375 additional shares in Pfizer during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 15, 2016. The investment management firm now holds a total of 21,474 shares of Pfizer which is valued at $786,807.Pfizer makes up approximately 0.27% of Capital Advantage’s portfolio.

Other Hedge Funds, Including , Btr Capital Management Inc reduced its stake in PFE by selling 170 shares or 0.11% in the most recent quarter. The Hedge Fund company now holds 150,443 shares of PFE which is valued at $5,512,232. Pfizer makes up approx 1.23% of Btr Capital Management Inc’s portfolio.Benin Management Corp boosted its stake in PFE in the latest quarter, The investment management firm added 750 additional shares and now holds a total of 21,082 shares of Pfizer which is valued at $765,487. Pfizer makes up approx 0.39% of Benin Management Corp’s portfolio.Exxonmobil Investment Management Inc Tx boosted its stake in PFE in the latest quarter, The investment management firm added 97,313 additional shares and now holds a total of 1,569,888 shares of Pfizer which is valued at $56,704,355. Pfizer makes up approx 1.18% of Exxonmobil Investment Management Inc Tx’s portfolio.Capital Insight Partners boosted its stake in PFE in the latest quarter, The investment management firm added 2,784 additional shares and now holds a total of 100,261 shares of Pfizer which is valued at $3,621,427. Pfizer makes up approx 3.41% of Capital Insight Partners’s portfolio.Iowa State Bank boosted its stake in PFE in the latest quarter, The investment management firm added 2,835 additional shares and now holds a total of 120,757 shares of Pfizer which is valued at $4,361,743. Pfizer makes up approx 2.21% of Iowa State Bank’s portfolio.

Pfizer closed down -0.13 points or -0.35% at $36.64 with 1,69,14,164 shares getting traded on Monday. Post opening the session at $36.69, the shares hit an intraday low of $36.55 and an intraday high of $36.99 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Pfizer reported $0.67 EPS for the quarter, beating the analyst consensus estimate by $ 0.12 according to the earnings call on May 3, 2016. Analyst had a consensus of $0.55. The company had revenue of $13005.00 million for the quarter, compared to analysts expectations of $12008.32 million. The company’s revenue was up 19.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.51 EPS.

Investors should note that on Jun 23, 2016, Pfizer announced a cash dividend of $0.3000. The company’s management has announced Aug 3, 2016 as the ex-dividend date and fixed the record date on Aug 5, 2016. The payable date has been fixed on Sep 1, 2016.

Many Wall Street Analysts have commented on Pfizer. Shares were Reiterated by Jefferies on Jun 20, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $42 .Berenberg Initiated Pfizer on May 12, 2016 to “Hold”, Price Target of the shares are set at $38.Company shares were Reiterated by UBS on May 4, 2016 to “Buy”, Firm has raised the Price Target to $ 38 from a previous price target of $36 .

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.